The phase III MATTERHORN trial, led by Janjigian et al., evaluated the addition of perioperative durvalumab, an anti–PD-L1 antibody, to standard chemotherapy in patients with resectable gastric and gastroesophageal junction adenocarcinoma. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.